Hindering The Progress Of Science: The Use Of The Patent System To Regulate Research On Genetically Altered Animals by Kambic, Robert B.
Fordham Urban Law Journal
Volume 16 | Number 3 Article 3
1988
Hindering The Progress Of Science: The Use Of
The Patent System To Regulate Research On
Genetically Altered Animals
Robert B. Kambic
Follow this and additional works at: https://ir.lawnet.fordham.edu/ulj
Part of the Intellectual Property Law Commons
This Article is brought to you for free and open access by FLASH: The Fordham Law Archive of Scholarship and History. It has been accepted for
inclusion in Fordham Urban Law Journal by an authorized editor of FLASH: The Fordham Law Archive of Scholarship and History. For more
information, please contact tmelnick@law.fordham.edu.
Recommended Citation
Robert B. Kambic, Hindering The Progress Of Science: The Use Of The Patent System To Regulate Research On Genetically Altered Animals,
16 Fordham Urb. L.J. 441 (1988).
Available at: https://ir.lawnet.fordham.edu/ulj/vol16/iss3/3
HINDERING THE PROGRESS OF SCIENCE:
THE USE OF THE PATENT SYSTEM TO
REGULATE RESEARCH ON GENETICALLY
ALTERED ANIMALS
I. Introduction
On April 17, 1987, the United States Patent and Trademark
Office (PTO) announced' that the PTO would begin accepting patent
applications on new forms of animal life created by genetic en-
gineering. 2 The PTO's new patenting policy initiated a ground swell
of controversy involving legal,3 economic,4 environmental' and eth-
1. See U.S. to Grant Patents on Animals, Wash. Post, Apr. 18, 1987, at A24,
col. 1 [hereinafter Patents on Animals]. The new patent policy was set forth in an
April 7, 1987, memorandum by Patent and Trademark Office Commissioner Donald
Quigg. See id. The announcement was prompted by the patent office appellate board's
ruling, four days earlier, in Ex parte Allen, 2 U.S.P.Q.2d 1425 (B.P.A.I. 1987). Id.
2. Genetic engineering refers to genetic manipulation technologies, such as the
recombinant deoxyribonucleic acid (DNA) technique. See Coordinated Framework
for Regulation of Biotechnology, 51 Fed. Reg. 23,302 (1986).
Cells of every living organism contain chromosomes. Each chromosome comprises
tens of thousands of genes strung next to each other in a chain. Genes are made
up of DNA, the genetic material determining the structure and biochemistry of all
living organisms. The DNA sequences found in genes determine which amino acids
and proteins are produced by cells which, in turn, produce the particular characteristics
of the entire organism. See generally OFFICE OF TECHNOLOGY ASSESSMENT, U.S. CONG.,
COMMERCIAL BIOTECHNOLOGY: AN INTERNATIONAL ANALYsIS 33-36 (1984) [hereinafter
OTA STUDY]; W. HEXTER & H. YOST, TiE SCIENCE OF GENETICS 285-321 (1976);
Talbot, Introduction to Recombinant DNA Research, Development and the Evolution
of the NIH Guidelines, and Proposed Legislation, 12 U. TOL. L. REv. 804, 804-14
(1981) [hereinafter Talbot].
A genetic engineer can isolate a specific gene from an organism and insert that
gene into the chromosome of another organism, altering its genetic code for a
particular characteristic. The specific gene is not added to a mature organism, but
to a single-cell fertilized egg. The egg divides into millions of cells resulting in a
mature organism. Each cell of the new organism contains the specific gene that was
added to the original egg. See Patents and the Constitution: Hearings Before the
Subcomm. on Courts, Civil Liberties and the Administration of Justice of the House
Comm. on the Judiciary, 100th Cong., 1st Sess. 3 (1987) (statement of T. Wagner,
Director of the Edison Animal Biotechnology Center at Ohio University, June 11,
1987) (these hearings were in response to the PTO's decision allowing animal patents)
[hereinafter Hearings: Patents].
3. See infra notes 161-81 and accompanying text.,
4. See infra notes 182-91 and accompanying text.
5. See infra notes 192-99 and accompanying text.
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ical issues.6 Although patents had previously been granted for
genetically altered bacteria,7 this marked the first time that patents
could be granted for animals genetically altered by man.8 Then,
on April 12, 1988, less than one year after the PTO's announcement,
the world's first animal patent was issued for a genetically altered
mouse. 9
In deciding to allow the patenting of genetically altered animals,
the PTO relied on the Supreme Court's recent decision in Diamond
v. Chakrabarty,10 in which the Court determined that patentable
subject matter included "anything under the sun that is made by
man."' 1 Chakrabarty's broad interpretation of patentable subject
matter led to a tremendous increase in the number of companies
doing research in the field of genetic engineering.12 With the promise
of patents to protect their investments, 3 researchers began inventing
genetically altered bacteria, 14 which yielded a variety of bene-
6. See infra notes 200-04 and accompanying text.
7. Recently obtained patents for genetically altered bacteria include U.S. Pat.
No. 4,362,816 (1982) (process for creating new microorganisms that produce insulin,
assigned to Upjohn Co.); U.S. Pat. No. 4,350,769 (1982) (microorganisms that produce
thickening agent for aqueous systems, assigned to Merck & Co., Inc.); U.S. Pat.
No. 4,259,444 (1981) (microorganisms that can digest crude oil, assigned to General
Electric Co.).
8. See New Animal Forms Will Be Patented, N.Y. Times, Apr. 17, 1987, at
A20, col. 1 [hereinafter New Animal Forms].
9. See Mouse Patent, a First, Issued to Harvard, N.Y. Times, Apr. 13, 1988,
at Al, col. 5 (U.S. Pat. No. 4,736,866 for "transgenic nonhuman mammals")
[hereinafter Mouse Patent]; Some Fear a Future of Animal Patents, Boston Globe,
Apr. 13, 1988, at 10, col. 3 ("the U.S. government this week crossed a Rubicon")
[hereinafter Future of Animal Patents]; see also A Mouse That Roared, Tn&m, Apr.
25, 1988, at 83 (first animal patent causes storm in Congress). For a discussion of
the new patent, see infra note 129 and accompanying text.
10. 447 U.S. 303 (1980); see "Animals-Patentability," Memorandum of Donald
Quigg, Commissioner of the Patent and Trademark Office, Apr. 7, 1987 (available
at Fordham Urban Law Journal office) [hereinafter PTO Memorandum].
11. Chakrabarty, 447 U.S. at 309 (quoting Committee Reports accompanying
Patent Act of 1952, S. REP. No. 1979, 82d Cong., 2d Sess. 5, reprinted in 1952
U.S. CODE CONG. & Armn. NEws 2394, 2399).
12. See Gore & Owens, The Challenge of Biotechnology, 3 YALE L. & POL'Y
REv. 336, 339 (1985) [hereinafter Gore]; M. KENNEY, BIoTECHNOL OGY: TrmE UM-
VERsrrY-INDUSTRIAL COMPLEX 190-91 (1986). In 1987, some four hundred firms,
representing an aggregate investment of over one billion dollars, participated in the
biotechnology industry. See Science Debates Using Tools to Redesign Life, N.Y.
Times, June 8, 1987, at A17, col. 1 [hereinafter Redesign Life].
13. The Patent and Trademark Office Commissioner's notice of July 29, 1980,
heralded the decision to apply Chakrabarty to patent applications for microorganisms.
997 OFF. GAZ. PAT. OFFICE 24 (Aug. 24, 1980).
14. Since 1980, the PTO has issued almost 200 patents on genetically altered
bacteria. See New Animal Forms, supra note 8, at A20, col. 2; see also Hutz, Patent
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fits. 5 For example, genetically altered microorganisms have been
utilized in cleaning up toxic waste and oil spills,16 protecting crops
from frost,'17 creating new beneficial drugs, 8 enhancing food
production 9 and furnishing a more efficient means to produce
chemicals. 20 Technology regarding genetically altered animals, it is
believed, promises even greater advances in scientific knowledge.2'
A coalition of animal rights activists, 22 farm lobbyists, 23 and
environmental24 and religious groups, 25 however, believe that the
potential benefits of genetically altered animals are overshadowed
by the potential dangers of this new technology. 26 The coalition
Protection for Living Organisms, 5 DEL. LAW. 30, 30 (1986) [hereinafter Hutz];
Gore, supra note 12, at 339.
15. See Hutz, supra note 14, at 30. See generally OTA STUDY, supra note 2, at
119-257; Karny, Regulation of Genetic Engineering: Less Concern about Frankensteins
But Time For Action on Commercial Production, 12 U. TOL. L. REv. 815 (1981).
16. Chakrabarty concerned the patentability of oil-eating microorganisms. 447
U.S. at 305; see also OTA STuDY, supra note 2, at 217-25 (use of genetically altered
microorganisms for pollution control).
17. See Recombinant DNA Research; Actions Under Guidelines, 48 Fed. Reg.
24,549 (1983) (release of strains of Pseudomonas syringae and Erwinia herbicola,
bacteria sprayed on crops to prevent freezing); OTA STUDY, supra note 2, at 184
(genetic material causing initiation of ice crystals was removed).
18. See OTA STUDY, supra note 2, at 119 (pharmaceutical industry is leader in
applications of new genetic technologies).
19. See id. at 183-84 (microorganisms produce insecticides and aid in disease
suppression to increase food production); SuBcoMM. ON INVESTIGATION AND OVERSIGHT
OF THE HousE Comm. ON SCIENCE AND TECHNOLOGY, 95TH CONG., 2D SEss., THE
ENVIRONMENTAL IMPLICATIONS OF GENETIC ENGINEERING 14 (Comm. Print 1984) (state-
ment of R. Hardy, Director of Life Sciences Research at Du Pont) (six billion people
will inhabit the earth by the year 2000).
20. See OTA STUDY, supra note 2, at 5, 195 (use of genetically altered bacteria
replaces traditional methods of chemical production).
21. See Hearings: Patents, supra note 2, at 4 (statement of M. Ostrach, Senior
Vice-President and General Counsel, Cetus Corp., Aug. 21, 1987); Mouse Patent,
supra note 9, at Al, col. 5 (genetically altered mouse presents scientists with more
efficient means for testing new drugs and therapies to treat cancer). See generally
OTA STuDY, supra note 2, at 119-257. For the purpose of this Note, an animal is
a multicellular organism that is not a plant or bacterium.
22. See infra notes 136-38 and accompanying text.
23. See infra notes 134-35 and accompanying text.
24. See infra notes 139-41 and accompanying text.
25. See infra notes 142-44 and accompanying text.
26. See Concern Over Genetics Prompts a New Coalition of Critics, N.Y. Times,
June 9, 1987, at Cl, col. 3 (promise and risk of genetic engineering) [hereinafter
New Coalition]; Religious Groups Join Animal Patent Battle, 237 SCIENCE 480, 480
(1987) (quoting A. Brouwer, General Secretary of the National Council of Churches)
("[t]he gift of life from God, in all its forms and species, should not be regarded
solely as if it were a chemical product, subject to genetic alteration and patentable
for economic benefit") [hereinafter Religious Groups Join].
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alleges that by patenting genetically altered animals, the animal
kingdom will be reduced to a commercial commodity27 with ge-
netically altered human beings next in line for ownership. 28
On the other hand, many groups support the patenting of ge-
netically altered animals. 29 Pharmaceutical firms, biotechnology
companies and many researchers believe that they must protect
their investments and move forward in an internationally compet-
itive field.30
The controversy surrounding the patenting of genetically altered
animals3 led to the introduction of a bill in Congress that would
impose a two-year moratorium on the issuance of such patents.32
Specifically, the moratorium pertains to patents that list animals
produced by artificial genetic manipulations as the patents' subject
matter.33
This Note considers whether animal inventions should be pro-
tected by the PTO and discusses the ramifications of a congres-
sionally imposed moratorium on the issuance of animal patents.
Part II of the Note discusses the purpose of the patent system and
analyzes case law concerning.patents on living organisms. Part III
examines the controversy surrounding the patenting of genetically
altered animals. Part IV examines the implications of patenting
genetically altered animals and contains a discussion of the PTO's
role in issuing an ethically controversial patent. Finally, the Note
concludes that the PTO was correct in determining that genetically
altered animals are patentable subject matter.
27. See Biotechnology's New Strain of Strife, INSIGHT, Aug. 31, 1987, at 56
(statement of J. Rifkin, President, Foundation on Economic Trends) [hereinafter
Strain of Strife].
28. See New Coalition, supra note 26, at C8, col. 1 (remarks of G. Annas,
Professor of Health Law at the Boston University School of Public Health) ("[Genetic
engineering] is a slippery slope. Where do we draw the line?").
29. See infra notes 145-54 and accompanying text.
30. See Hearings: Patents, supra note 2, at 5-7 (statement of W. Duffey on
behalf of Intellectual Property Owners, Inc. and Industrial Biotechnology Association,
July 22, 1987); id. at 2 (statement of N. Seay, Professor of Patent Law at the
University of Wisconsin Law School, Aug. 21, 1987).
31. See infra notes 130-60 and accompanying text.
32. 133 CONG. REc. H7206 (daily ed. Aug. 5, 1987) (statement of Rep. Rose);
see New Bill Seeks 2-Year Delay For Any Patents for Animals, N.Y. Times, Aug.
6, 1987, at A18, col. 1 [hereinafter New Bill).
33. H.R. 3119, 100th Cong., 1st Sess. (1987) (introduced by Rep. Rose); see New
Bill, supra note 32, at A18, col. 1 (same). This is the first time in the 197-year
history of the patent system that legislation has been proposed to block a policy
that the PTO has already put into effect. Id.
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II. Background
For almost 200 years the United States patent system has en-
couraged inventors to invest in new, high-risk technology by offering
temporary protection from invention thieves.34 This encouragement
continued in the technological field of genetic engineering by af-
fording new bacterium inventions patent protection." When genetic
engineers focused their innovative skills on animals, 6 the PTO
continued to encourage research by protecting the scientists' new
inventions."
A. The Patent System
Congress created the patent system in 1790 as the legal instru-
ment to promote innovation in the technological sciences.3" The
Constitution authorizes Congress "to promote the [p]rogress of
[s]cience and the useful [airts, by securing for limited [tjimes to
[a]uthors and [i]nventors the exclusive [flight to their respective
[w]ritings and [d]iscoveries" 3 9 and "[to] make all [liaws which shall
be necessary and proper for carrying into [e]xecution the
foregoing [p]owers. "40 Thomas Jefferson, who was instrumental
in drafting this provision, felt that ingenuity should be liber-
ally encouraged 41 and, accordingly, one should receive a patent
for inventing or discovering any useful art, 42  manufac-
34. See 1 A. WALKER, WALKER ON PATENTS § 1:9, at 57 (E. Lipscomb 3d ed.
1984) (the first Patent Act was enacted in 1790) [hereinafter WALKER]. A patent
allows an inventor to exclude all others from making, using or selling his or her
invention for seventeen years. 35 U.S.C. § 154 (1982).
35. See supra notes 13-14 and accompanying text.
36. See Talbot, supra note 2, at 806 (higher organisms are next class to be
explored).
37. See PTO Memorandum, supra note 10, at 1 (PTO considers animals to be
patentable subject matter); see also OTA STUDY, supra note 2, at 400-01 (promotion
of genetic engineering through patents).
38. See 1 WALKER, supra note 34, § 1:9, at 57-58 (Thomas Jefferson spoke highly
of First Patent Act of 1790).
39. U.S. CONST. art. I, § 8, cl. 8.
40. Id. § 8, cl. 18.
41. See 1 WALKER, supra note 34, § 1:9, at 58, § 2:1, at 72.
42. "Art" is included in the definition of process. See 35 U.S.C. § 100(b) (1982);
1 WALKER, supra note 34, § 2:4, at 103. In Cochrane v. Deener, 94 U.S. 780 (1876),
the Supreme Court defined a process as "[a] mode of treatment of certain materials
to produce a given result .... The process requires that certain things should be
done with certain substances, and in a certain order; but the tools to be used in
doing this may be of secondary consequence." Id. at 788. It should be noted that
the process or method itself is patentable subject matter and the claim need not
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ture,43 machine,' 4 device or any improvement thereof not before
known or used. 45 The current Patent Act, 46 which was enacted in
1952,'4 preserves these basic, liberal requirements. 48
When filing a patent application with the PTO, an applicant
must set forth a statement satisfying certain requirements of the
Patent Act.4 9 Section 101 of the Patent Act5° provides the first
requirement for patentability: "Whoever invents or discovers any
new and useful process, machine, manufacture, or composition of
matter, or any new and useful improvement thereof, may obtain
a patent therefor, subject to the conditions and requirements of
this title."'" This first requirement contains three separate and
distinct elements: novelty, 3 utility 4 and patentable subject mat-
ter. 5 While section 101 states that the invention must be new,
section 10256 deals exclusively with the issue of novelty." Conse-
quently, one does not have to show novelty of invention to satisfy
the section 101 requirement of patentability. The novelty element
of section 101 focuses on whether the invention presents a new
patentable subject matter,5 9 as opposed to the section 102 require-
ment which seeks a comparison with prior inventions to determine
involve a structure or end product. See Dennison Mfg. Co. v. Ben Clements & Sons,
Inc., 467 F. Supp. 391, 405 (S.D.N.Y. 1979).
43. See infra note 70 and accompanying text.
44. See infra note 69 and accompanying text.
45. See Maloney-Crawford Tank Corp. v. Sauder Tank Co., 465 F.2d 1356, 1365
(10th Cir. 1972). An improvement is some variance, simplification or addition that
is new and different from existing machines, processes or manufactures. See 1 WALKER,
supra note 34, § 2:10, at 148.
46. 35 U.S.C. §§ 100-376 (1982) (Patent Act of 1952).
47. Id.
48. See Diamond v. Chakrabarty, 447 U.S. 303, 308-09 (1980); In re Bergy, 596
F.2d 952, 973-74 (C.C.P.A. 1979), dismissed as moot sub nom. Diamond v. Chak-
rabarty, 444 U.S. 1028 (1980).
49. See 35 U.S.C. § 112 (1982) (specification of new invention).
50. Id. § 101.
51. Id. "The first door which must be opened on the difficult path to patentability
is § 101." Bergy, 596 F.2d at 960.
52. See Bergy, 596 F.2d at 960.
53. See infra note 73 and accompanying text.
54. See infra notes 62-66 and accompanying text.
55. See infra notes 67-71 and accompanying text.
56. 35 U.S.C. § 102 (1982) (patentability conditions for novelty and loss of right
to patent).
57. See Bergy, 596 F.2d at 961.
58. See In re Waldbaum, 457 F.2d 997, 1002-03 (C.C.P.A. 1972) (court discusses
"new" uses under patent statutes).
59. See Diamond v. Diehr, 450 U.S. 175, 188-91 (1981) (the novelty of an invention
is examined in § 102 and not in § 101).
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if the invention is actually "new." ' 60 The two remaining elements,
utility and subject matter, must also be satisfied under section 101.61
The utility element of section 101 requires that the invention:
(1) have a known purpose that is either apparent from the de-
scription of the invention in the patent application or, if not
apparent, is specifically recited in the application; 62 and (2) operate
to perform its intended pupose or function. 63 This second aspect
of the utility element, operability, requires that patent application
statements regarding the performance of the invention for its in-
tended purpose be "believable on its face to persons skilled in the
art in view of contemporary knowledge." ' 64 The inventor must
submit "adequate proof ' 65 of the invention's operability through
affidavits of experts, test results or a model of the invention. 66
The subject matter element of section 101 requires that the
invention fit into one of four categories: a process, a machine, a
manufacture or a composition of matter. 67 The term "process" is
defined in section 100(b) as a "process, art or method, and includes
a new use of a known process, machine, manufacture, composition
of matter, or material." 6 A "machine" is defined as any mechanical
contrivance designed to perform some function. 69 The term "man-
ufacture" means the production of articles from raw materials
produced by changing the raw materials into new forms, giving
them new qualities, properties or combinations. 70 A "composition
60. See id.; see also Waldbaum, 457 F.2d at 1002-03; 1 WALKER, supra note 34,
§ 4:4, at 269-70. An invention is not novel if before it was invented it was "known
or used by others in this country, or patented or described in a printed publication
in this or a foreign country . . . ." 35 U.S.C. § 102(a) (1982).
61. See In re Bergy, 596 F.2d 952, 961 (C.C.P.A. 1979), dismissed as moot sub
nom. Diamond v. Chakrabarty, 444 U.S. 1028 (1980).
62. See 1 WALKER, supra note 34, § 5:4, at 490-91 (comprehensive definition of
"useful" is difficult to convey).
63. See id.
64. See Hearings: Patents, supra note 2, at 3 (statement of R. Tegtmeyer, Assistant
Commissioner of PTO, June 11, 1987).
65. See 1 WALKER, supra note 34, § 5:17, at 558-59 (admissibility of utility requires
any competent evidence).
66. See Hearings: Patents, supra note 2, at 3-4 (statement of R. Tegtmeyer,
Assistant Commissioner of PTO, June 11, 1987).
67. 35 U.S.C. § 101 (1982); see also Parker v. Flook, 437 U.S. 584, 584-96 (1978)
(holding computerized method of updating alarm limits outside four categories of
§ 101 subject matter).
68. 35 U.S.C. § 100(b) (1982); see also 1 WALKER, supra note 34, § 2:4, at 102-
03; Cochrane v. Deener, 94 U.S. 780, 788 (1877) ("[a] process is a mode of treatment
of certain materials to produce a given result").
69. See 1 WALKER, supra note 34, § 2:7, at 134-35.
70. See id. § 2:8, at 139 (the term "manufacture" does not include processes,
machines and compositions of matter).
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of matter" is construed to mean all composite articles, whether
they are the result of gases, fluids or powders, or mechanical
mixtures.71
After satisfying the elements of section 101, the inventor must
meet the "novelty" and "nonobvious" requirements of section 102
and 103, respectively. 72 "Novelty" means that a patent can only
be obtained if the identical subject matter did not exist in a prior
art.71 "Nonobviousness" means that a patent can only be obtained
if differences exist between the invention and the prior art to the
extent that one skilled in the relevant art, at the time the invention
was made, would not conclude that the invention as a whole is
equivalent to the prior art. 74
Finally, the patent applicant must comply with the disclosure
and claiming requirements of section 112 .7 Section 112 requires
that the patent application describe the invention in such a manner
that one skilled in the relevant art can make and use the invention
without the exercise of independent inventive skills. 76 Furthermore,
the patent application, in one or more claims, must set forth
particularly and distinctly the subject matter of the invention. 77
B. Patentability of Living Organisms
1. Pre-Chakrabarty Treatment of Living Organisms
The PTO has been issuing patents on living matter for more
than a century.78 For example, in 1873, the PTO issued patent
71. See id. § 2:9, at 143-44; see also Diamond v. Chakrabarty, 447 U.S. 303,
308 (1980) (Supreme Court's definition of "composition of matter" is consistent with
its common usage).
72. 35 U.S.C. §§ 102-103 (1982); see In re Bergy, 596 F.2d 952, 961 (C.C.P.A.
1979), dismissed as moot sub nom. Diamond v. Chakrabarty, 444 U.S. 1028 (1980)
(§ 102 and § 103 are the second and third doors that must be opened to obtain a
patent).
73. See 35 U.S.C. § 102 (1982); see also 1 WALKER, supra note 34, § 4:1, at
258-59.
74. 35 U.S.C. § 103 (1982). For a discussion of "nonobviousness" and § 103,
see Graham v. John Deere Co., 383 U.S. 1, 12-19 (1966).'
75. See 35 U.S.C. § 112 (1982). See generally 3 WALKER, supra note 34, § 10:1,
at 182-87.
76. See 35 U.S.C. § 112 (1982).
77. See id.
78. See In re Bergy, 596 F.2d 952, 985 (C.C.P.A. 1979), dismissed as moot sub
nom. Diamond v. Chakrabarty, 444 U.S. 1028 (1980); I. COOPER, BIOTECHNOLOGY
AND T=E LAW § 2.02, at 2-5 (1982) [hereinafter COOPER]; Hutz, supra note 14, at
34 .n.3.
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141,072 to Louis Pasteur for his invention of a pure culture of
yeast.7 9 Since 1873, several patents involving living organisms were
issued by the PT s0° which recognized that living organism inventions
were a result of human ingenuity and research, and hence, fully
protected by the patent statutes. 81
The PTO's practice of issuing patents on living "processes" was
first challenged in Guaranty Trust Co. v. Union Solvents Corp. ,8' 2
a patent infringement case. 3 In Guaranty Trust Co., the infringer
attacked the validity of a patent issued for a bacteriological process
used in making acetone and alcohol,8 4 alleging that a "life process
of a living organism" does not constitute patentable subject matter. 5
The court rejected this argument and held that life processes were
patentable subject matter.16 The appellate court affirmed the de-
cision because it was persuaded "that the invention disclosed in
the patent created a new and important commercial enterprise [which
should be protected against infringement] . *... ,8
The patenting of a living "process," however, was not without
restrictions. The PTO would not issue a patent on a naturally
occurring process, a "handiwork of nature." 8 8 Even when the
process used an organism that expressed traits not typically exhibited
in nature, if the traits were a natural property of the organism,
the process that used the organism could not be patented. 9 Fur-
thermore, merely because a non-natural living process was found
to be patentable, the microorganism used in that living process was
79. See COOPER, supra note 78, at 2-5 to -6; Biggart, Patentability in the United
States of Microorganisms, Processes Utilizing Microorganisms, Products Produced by
Microorganisms and Microorganism Mutational and Genetic Modification Techniques,
22 IDEA 113, 114 (1981) [hereinafter Biggart].
80. See, e.g., COOPER, supra note 78, at 2-6 & n.14 (list of patents issued by
the PTO on living organisms); Biggart, supra note 79, at 114-15 (patents of living
matter issued before Chakrabarty).
81. See Ex parte Prescott, 19 U.S.P.Q. 178, 180-81 (P.B.A. 1932). But see Funk
Bros. Seed Co. v. Kala Inoculant Co., 333 U.S. 127 (1948). In Funk Bros., which
considered a claim to a mixture of bacteria, the Supreme Court invalidated the
relevant patent for want of invention because the mixture was a natural phenomenon.
Id. at 131-32. Although the organisms expressed traits not exhibited in nature, these
were natural properties of the organisms whose discovery failed to warrant the issuance
of a patent. Id. at 130-31.
82. 54 F.2d 400 (D. Del. 1931), aff'd, 61 F.2d 1041 (3d Cir. 1932).
83. Id. at 401.
84. Id.
85. Id. at 410.
86. Id.
87. Guaranty Trust Co., 61 F.2d at 1041.
88. Funk Bros. Seed Co. v. Kala Inoculant Co., 333 U.S. 127, 130-31 (1948).
89. Id.
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not necessarily patentable. 90 Indeed, prior to 1980, the lowest form
of an organism, a bacterium, was not patentable subject matter
under section 101. 91
One of the earliest cases discussing whether animals were pat-
entable subject matter under section 101 was In re Merat.92 In that
case, the inventor sought to patent a dwarf chicken which was
produced by a controlled breeding method, 93 not by genetic im-
plantation of a dwarfism gene. The PTO refused to grant the
patent, holding that a thing occurring in nature that was produced
by controlled propagation is not a "manufacture" and, therefore,
not patentable under section 101. 94
In affirming the PTO's decision in In re Merat, the Board of
Patent Appeals (BPA)95 agreed that the subject matter requirement
of section 101 was not satisfied. 96 The United States Court of
Customs and Patent Appeals (CCPA), however, failed to address
whether the dwarf chicken met the requirement of section 101
because the court affirmed the PTO's decision on other grounds. 97
In 1979, the CCPA reached a decision on whether non-naturally
occurring microorganisms are patentable subject matter under sec-
90. See Comment, Bergy, Flook and Microorganisms as Patentable Products, 29
CATH. U.L. REv. 485, 490-91 (1980) (discussing In re Mancy, 499 F.2d 1289 (C.C.P.A.
1974)).
91. See 997 OFF. GAz. PAT. OFFICE 24 (Aug. 24, 1980) (previously suspended
microorganism patent applications are now being examined); Hutz, supra note 14,
at 33 (before 1980 PTO refused to allow bacteria patents). Bacteria, however, did
become patentable as a result of the Chakrabarty decision. See supra note 10 and
accompanying text.
92. 519 F.2d 1390 (C.C.P.A. 1975).
93. Id. at 1391.
94. Id. at 1393.
95. In 1984, the BPA and the Board of Patent Interferences (BPI) were combined
into the Board of Appeals and Interferences. See 4 WALKER, supra note 34, § 12:56,
at 242 n.18.
After a rejection of a patent application by a patent examiner, the applicant may
appeal to the Board of Patent Appeals and Interferences (BPAI). If the BPAI's
decision is adverse, the patent applicant may appeal to the Court of Appeals for
the Federal Circuit (CAFC), which was created in 1982 by joining the Court of
Claims and the Court of Customs and Patent Appeals (CCPA). The CAFC's decision
cannot be appealed but it may be reviewed by the United States Supreme Court.
See id. §§ 12:55-56, at 240-43, § 12:58, at 279-80.
96. See In re Merat, 519 F.2d 1390, 1393 (C.C.P.A. 1975).
97. See id. at 1394. The CCPA rejected the patent for failing to distinctly claim
the subject matter as required by 35 U.S.C. § 112 (1982). Id.
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tion 101.98 In In re Bergy9 9 and its companion case, In re Chak-
rabarty,100 the court held that non-naturally occurring microorganisms
were within the patentable subject matter requirement of section
101.101 The court further stated that no patent application should
be rejected on the sole ground that the application involves a living
organism.' °2 The court concluded:
We see no sound reason to refuse patent protection to the
microorganisms themselves, or to pure microorganism cultures,
... when they are new and unobvious. In fact, we see no legally
significant difference between active chemicals which are clas-
sified as "dead" and organisms used for their chemical reactions
which take place because they are "alive".... We think the
purposes underlying the patent system require us to include
microorganisms and cultures within the terms "manufacture"
and "composition of matter" in [section] 101.103
The court stated that the role of the judiciary did not include
imposing non-congressional limitations and restrictions on the patent
laws. 104
98. See Bergy, 596 F.2d at 973. The patent applied for in Bergy was for a
biologically pure culture of the microorganism Streptomyces vellosus that produces
the antibiotic lincomycin. See id. at 967.
99. 596 F.2d 952 (C.C.P.A. 1979), dismissed as moot sub nom. Diamond v.
Chakrabarty, 444 U.S. 1028 (1980).
100. 596 F.2d 952 (C.C.P.A. 1979), aff'd sub nom. Diamond v. Chakrabarty, 447
U.S. 303 (1980).
101. Bergy, 596 F.2d at 987. The CCPA reversed the decision of the Board of
Patent Appeals in both In re Bergy, 563 F.2d 1031 (C.C.P.A. 1977) [hereinafter
Bergy 1], vacated sub nom. Parker v. Bergy, 438 U.S. 902 (1978), aff'd on rehearing,
In re Bergy, 596 F.2d 952 (C.C.P.A. 1979), dismissed as moot sub nom. Diamond
v. Chakrabarty, 444 U.S. 1028 (1980), and In re Chakrabarty, 571 F.2d 40 (C.C.P.A.
1978) [hereinafter Chakrabarty 1], aff'd on rehearing sub nom. In re Bergy, 596
F.2d 952 (C.C.P.A. 1979), aff'd sub nom. Diamond v. Chakrabarty, 447 U.S. 303
(1980), holding that the invention claims defined subject matter within § 101. See
Bergy I, 563 F.2d at 1036; Chakrabarty 1, 571 F.2d at 43.
The Supreme Court vacated the CCPA's judgment in Bergy I and remanded it
to the CCPA for further consideration in light of Parker v. Flook, 437 U.S. 584
(1978). Flook sought to patent a method for correcting the value of alarm limits
during catalytic conversion of hydrocarbons. This method involved using a novel
mathematical formula Flook had discovered. See id. at 585-86.
After the remand of Bergy I, the CCPA vacated its decision in Chakrabarty I
and because of the similarity of the cases the CCPA reheard Bergy I and Chakrabarty
I together. See In re Bergy, 596 F.2d 952 (C.C.P.A. 1979), dismissed as moot sub
nom. Diamond v. Chakrabarty, 444 U.S. 1028 (1980).
102. Bergy, 596 F.2d at 975.
103. Id. (emphasis in original).
104. Id. at 987 (court's statement is based on United States v. Dubilier Condenser
Corp., 289 U.S. 178, 199 (1933)).
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2. The Chakrabarty Court's Treatment of Living Organisms
In 1980, the Supreme Court agreed to hear Diamond v. Chak-
rabarty.105 The Court affirmed the CCPA's determination that a
live, human-made microorganism is patentable subject matter under
section 101.106
After reviewing the legislative history of section 101, the Supreme
Court held that Congress intended the section to be construed
broadly. 107 Patentable subject matter was to "include anything under
the sun that is made by man."' 18 The Court then stated that
Congress, when determining the patentability of inventions, focused
not on the distinction "between living and inanimate things, but
between products of nature, whether living or not, and human-
made inventions." 109
The specific organisms with which the Court was concerned were
genetically engineered bacteria not found in nature."10 The bacteria,
capable of breaking down multiple components of crude oil, were
invented to aid in fighting oil spills on large bodies of water."'
Because these organisms were genetically altered by man and could
not be found in nature, the Court held that the bacteria were
patentable subject matter under section 101.112
3. Post-Chakrabarty Treatment of Living Organisms
With Chakrabarty in hand and with the tacit consent of Congress,
the PTO began to issue patents on genetically altered microorgan-
isms." 3 Experts predicted that it was only a matter of time before
105. 447 U.S. 303 (1980). Although writ was granted to both Bergy and Chak-
rabarty, Bergy was dismissed as moot. 444 U.S. 1028 (1980).
106. Id. at 309-10.
107. Id. at 308-09.
108. See supra note 11 and accompanying text.
109. 447 U.S. at 313.
110. See id. at 305.
111. See id. In Chakrabarty's patent applications, in addition to claiming a process
using a new organism, he claimed a new form of the bacterial genus Pseudomonas
capable of digesting crude oil. See Chakrabarty I, 571 F.2d at 41-42.
112. See Chakrabarty, 447 U.S. at 309-10.
113. Almost two hundred patents have been granted ori genetically altered bacteria
since the Chakrabarty decision. See supra notes 7, 15 and accompanying text. Many
new biotechnology companies emerged in reliance'on this apparent stamp of approval
by the government. See Pinon, Recombinant DNA: Controversy and Promise, A
Scientist's Overview, in FROM RESEARCH TO REVOLUTION 8 (R. Bohrer ed. 1987);
Gore, supra note 12, at 339. In 1987 almost four hundred companies were seeking
to develop products based on genetic engineering technology. See Redesign Life,
supra note 12, at A17, col. 1.
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applicants would assert that higher life-form inventions were within
the scope of section 101's patentable subject matter." 4
In 1984, the PTO received a patent application requesting patents
on both the method of inducing polyploidy"5 in oysters and the
resulting polyploid oyster." 6 The patent examiner for the PTO
approved the claim for the method of inducing polyploidy." '7 The
patent examiner, however, rejected the patent claim for the pol-
yploid oyster, concluding that an inventor's oyster is not patentable
subject matter under section 101.118 The examiner found that the
polyploid oyster was a living entity that is "controlled by the laws
of nature and not a manufacture by man that is patentable."" 9
In Ex parte Allen, the Board of Patent Appeals and Interferences
(BPAI), the appellate review board for the PTO, reversed the patent
examiner's section 101 rejection of the claim. 20 The BPAI based
its reversal on Chakrabarty's determination that section 101 included
non-natural human-made life forms.' 21 The BPAI used the Chak-
rabarty test for determining whether an invention is patentable
under section 101 '-if a human-made invention cannot be found
in nature, the invention is patentable subject matter., Ex parte
Allen thus upheld, for the first time, the patenting of higher life
organisms by the PTO.2 4
114. See COOPER, supra note 78, § 6.02, at 6-3 to -8; see also OTA STrDY, supra
note 2, at 386 (patentable subject matter determined on case-by-case basis).
115. A polyploid organism is an organism with more than two sets of chromosomes;
humans have two sets and are diploid. See W. KEETON, ELEMENTS OF BIOLOGICAL
SCIENCE 528 (1972).
116. Ex parte Allen, 2 U.S.P.Q.2d 1425 (B.P.A.I. 1987). Polyploidy in oysters
causes sterility, increasing the oysters' size, and making them edible year-round. See
id. at 1428.
117. Id. at 1425-26 (claims 1 and 9 involved the method of producing polyploid
oysters and were patentable).
118. Id. (claims 8, 12, 13 & 14 involved the actual polyploid oyster and were
rejected).
119. Id. at 1426. The oyster was also rejected under § 103 for being obvious to
one of ordinary skill in the art. Id. at 1427.
120. Id. at 1426-27.
121. Id.
122. See id.
123. See id. at 1427 (citing Chakrabarty, 447 U.S. at 313).
124. See Patents on Animals, supra note 1, at A24, col. 1. The BPAI, however,
affirmed the examiner's rejection of the patent claim based on the obviousness of
the invention under § 103. Consequently, a patent was not issued for this oyster.
See Allen, 2 U.S.P.Q.2d at 1427. The court stated that "[ijf the product in a product-
by-process claim is the same as or obvious from a product of the prior art, the
claim is unpatentable even though the prior product was made by a different process."
Id.
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III. The Controversy Surrounding the Patentability of Animals
A. The PTO Announcement Concerning Animal Patentability
Based on the BPAI's decision in Ex parte Allen, the Assistant
Secretary and Commissioner of Patents and Trademark announced
on April 17, 1987, that the "Patent and Trademark Office now
considers non-naturally occurring non-human multicellular living
organisms, including animals, to be patentable subject matter within
the scope of 35 U.S.C. [section] 101. ' z125 The Commissioner ex-
plicitly stated that any claim that human life is patentable under
section 101 would be rejected because the grant of a property right
in a human being would be prohibited by the Constitution.12 6 The
thirteenth amendment forbids involuntary servitude, and therefore
a person cannot own another human being.1 27
The PTO's new policy to allow the patenting of animals was
implemented on April 12, 1988, when the PTO issued its first
animal patent.121 The patent was for a genetically altered mouse
invented at Harvard Medical School. The Harvard researchers in-
vented a mouse that is prone to develop cancer, enabling researchers
to learn more about the disease. 29
B. The Response to a Controversial Decision
1. A Coalition of Critics
The PTO's decision to review patents on animals triggered a
storm of controversy. 30 A coalition in opposition to the use of
125. PTO Memorandum, supra note 10, at 1; see supra note 1 and accompanying
text.
126. PTO Memorandum, supra note 10, at 1.
127. See U.S. CONST. amend. XIII, § 1. But see OFFICE OF TECHNOLOGY
ASSESSMENT, U.S. CONG., NEW DEVELOPMENTS IN BIOTECHNOLOGY: OWNERSHIP OF
HUMAN TIssuEs AND CELLS 70-71 (1987).
128. See supra note 9 and accompanying text.
129. See Future of Animal Patents, supra note 9, at 10, col. 1. The scientists who
invented the mouse were Dr. P. Leder, Chairman of Harvard Medical School's
Department of Genetics, and Dr. T. Stewart, a scientist at Genentech Inc. in San
Francisco. Id. A gene that causes cancer in many mammals, including humans, was
isolated by the two researchers. This gene was then injected into a fertilized mouse
egg that developed into the patented mouse. See Mouse Patent, supra note 9, at
Al, col. 5. "Because half the females develop cancer, the altered breed serves as a
more effective model for studying how genes contribute to the development of cancer,
particularly breast cancer." Id. (statement of P. Leder).
130. See New Coalition, supra note 26, at Cl, col. 3; Strain of Strife, supra note
27, at 56.
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genetic engineering in altering the genes of animals 3' quickly began
lobbying Congress to narrow the patent law and exclude animals
from patentable subject matter.'32 The coalition has alleged that
such patents will wipe out small farmers who cannot afford ge-
netically altered livestock, encourage animal experimentation, and
"lead to a Brave New World in which people [will] hold patents
on other people."' 33
Several farm organizations are concerned with the possibility that
animal patents will accelerate the decline of the small, family-owned
farm. 34 In short, the organizations assert that a few large cor-
porations, which have the assets to invest in genetically altered
animals, will push the small farmer out of business. 3 '
Animal rights groups contend that the patenting of genetically
altered livestock will "[unleash] the potential for uncontrollable
and unjustified animal suffering."' 3 6 These groups believe that the
patenting of animals will result in the elimination of less desirable
breeds leading ultimately to a loss of genetic diversity within a
species.'37 They further assert that the loss of certain beneficial
genes will shrink the available gene pool and cause an increase in
epidemics. 3'
131. See New Coalition, supra note 26, at CI, col. 3. The coalition includes many
diverse organizations: the Humane Society of the United States, the National Fed-
eration of Churches, the National Wildlife Federation, the Foundation on Economic
Trends, and the National Farmers Union. See Organizations and Individuals Supporting
Legislation to Halt the Patenting of Animals (Nov. 19, 1987) (information received
from the Foundation on Economic Trends) (available at Fordham Urban Law Journal
office).
132. See Religious Groups Join, supra note 26, at 480; see also Hearings: Patents,
supra note 2, at 2 (statement of J. Hoyt, President of the Humane Society of the
United States, June 11, 1987).
133. See Should Man Make Beast?, NEWSWEEK, May 4, 1987, at 72 [hereinafter
Man Make Beast].
134. See Hearings.- Patents, supra note 2, at 3-4 (statement of D. Schwarze on
behalf of the Wisconsin Family Farm Defense Fund, Inc., Aug. 21, 1987); id. at 3
(statement of S. Huber on behalf of the Farmers Union Milk Marketing Cooperative
and the Wisconsin Farmers Union, Aug. 21, 1987); id. at 2 (statement of A. Sorenson,
Assistant Director, Natural & Environmental Resources Division, American Farm
Bureau Federation, July 22, 1987).
135. See id. at 1-2 (statement of T. Saunders on behalf of the Wisconsin Farm
Alliance, Aug. 21, 1987); id. at 1 (statement of J. Rifkin, President, Foundation on
Economic Trends, Nov. 5, 1987). /
136. See Hearings. Patents, supra note 2, at 4 (statement of J. Hoyt, President
of the Humane Society of the United States, June 11, 1987).
137. See id. at 5.
138. See id. at 3 (statement of S. Huber on behalf of the Farmers Union Milk
Marketing Cooperative and the Wisconsin Farmers Union, Aug. 21, 1987); id. at 2
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The National Wildlife Federation (NWF) is concerned with the
patenting of genetically altered animals that are intended to be
released into the wild. 3 9 The NWF claims that the release of
genetically altered animals, such as fish developed for fish stocking,
may have a serious impact on existing wildlife.140 Similarly, envi-
ronmentalists contend that, because genetically altered animal tech-
nology is still in its infancy, little is known about the potential
effect of genetically altered animals on the environment.1 41
The patenting of genetically altered animals is also causing alarm
in America's religious community. 142 The National Council of
Churches (NCC) firmly supports a moratorium on the issuance of
genetically altered animal patents. 143 The NCC contends that genetic
engineering is advancing so rapidly that society has not had time
to consider the ethical and moral questions raised by such tech-
nology. 144
2. A Coalition of Supporters
Among those supporting the PTO's decision are pharmaceutical
firms, biotechnology companies and researchers. 45 The proponents
believe that patents will be critical to the success of companies
working with high-risk technology. 46 Patents are believed to be the
proper tools for turning laboratory experimentation into useful
products that will benefit society.147 Indeed, these groups maintain
(statement of A. Sorenson, Assistant Director, Natural & Environmental Resources
Division, American Farm Bureau Federation, July 22, 1987); see also OTA STUDY,
supra note 2, at 494.
139. See Hearings: Patents, supra note 2, at 4 (statement of M. Mellon, Manager
of the Biotechnology Project of the National Wildlife Federation, Nov. 5, 1987).
140. See id.
141. See id.
142. See Religious Groups Join, supra note 26, at 480.
143. See id.; see also Hearings: Patents, supra note 2, at 4 (statement of Rev.
W. Granberg-Michaelson on behalf of the National Council of Churches, Nov. 5,
1987).
144. See Hearings: Patents, supra note 2, at 4 (statement of Rev. W. Granberg-
Michaelson on behalf of the National Council of Churches, Nov. 5, 1987). The
General Secretary for the NCC has stated that "[o]ur culture's stance toward the
gifts of God's creation, and our respect for all life, call for thoughtful reflection
and judgment on these matters by churches and religious institutions .... " Id. at
app. (statement of religious leaders against animal patenting, endorsed by twenty-
four religious organizations).
145. See Strain of Strife, supra note 27, at 56.
146. See Hearings: Patents, supra note 2, at 19 (statement of G. Karny, intellectual
property attorney, editor of Biotechnology Law Report, Nov. 5, 1987).
147. See id. at 18; see also id. at 1 (statement of R. Adler, intellectual property
attorney, July 22, 1987).
456
ANIMAL PA TENTS
that the prohibition or delay of patents on genetically altered
animals could seriously delay new life-saving medicines and prevent
major agricultural innovations.148
The American Farm Bureau Federation (AFBF), the largest gen-
eral farm organization in the United States, is in favor of patenting
genetically altered animals. 149 The AFBF believes that the role of
genetic engineering in animal production will cause a reduction in
farm costs and expand the utilization of farm products. 150 The
AFBF supports the PTO's announcement because it claims that
denying patents would deliberately delay genetically altered animal
technology merely to calm unproven fears."'
Finally, proponents argue that animal patents will help society
cope with the attendant problems of a continuing increase in the
world population. Specifically, those in favor of animal patents
point to the need for food suppliers to produce more food in the
next forty years than they have since the beginning of modern
agriculture,5 2 and the need to discover cures for complex diseases
which continue to threaten human life.' Indeed, the Supreme Court
148. See Hearings: Patents, supra note 2, at 3 (statement of A. Smith, Vice-
President of Integrated Genetics Inc., Nov. 5, 1987); id. at 20 (statement of G.
Karny, intellectual property attorney, editor of Biotechnology Law Report, Nov. 5,
1987). "I don't really understand the concern .... If I could understand it perhaps
I could argue against it. There's some blind, gut feeling that somehow it ain't right.
But to me it isn't right to stand by while thousands of American women die of
cancer." Future of Animal Patents, supra note 9, at 10, col. 5 (statement of P.
Leder, Chairman of the Department of Genetics at Harvard Medical School) (discussing
concerns of animal patent opponents).
149. See Hearings: Patents, supra note 2, at 13 (statement of A. Sorenson, Assistant
Director, Natural & Environmental Resources Division, American Farm Bureau Fed-
eration, July 22, 1987); Strain of Strife, supra note 27, at 57.
150. See Hearings: Patents, supra note 2, at 1 (statement of A. Sorenson, Assistant
Director, Natural & Environmental Resources Division, American Farm Bureau Fed-
eration, July 22, 1987). The use of genetic engineering in animal husbandry allows
farmers to achieve the uniform quality of product that was once confined to man-
ufacturers. See Cloning Offers Factory Precision to the Farm, N.Y. Times, Feb. 17,
1988, at Al, col. 3.
151. Hearings: Patents, supra note 2, at 1 (statement of A. Sorenson, Assistant
Director, Natural & Environmental Resources Division, American Farm Bureau Fed-
eration, July 22, 1987).
152. See id. at 2 (statement of W. Brill, Vice-President of Research and Devel-
opnfient, Agracetus Co., Aug. 21, 1987) (U.S. government must help agriculture in
meeting food production challenges); id. at 1 (statement of R. Adler, intellectual
property attorney, July 22, 1987) (world population of almost five billion projected
to double within fifty years).
153. See id. at 3 (statement of A. Smith, Vice-President of Integrated Genetics
Inc., Nov. 5, 1987) (moratorium on patents will hinder beneficial health care de-
velopments); id. at 7-8 (statement of T. Wagner, Director of the Edison Animal
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in Chakrabarty stated that the issuance of patents to foster pro-
ductive efforts by inventors "will have a positive effect on society
through the introduction of new products and processes of man-
ufacture into the economy, and the emanations by way of increased
employment and better lives for our citizens.' ' 4
3. Congressional Action
As a result of the controversy caused by the PTO's announcement,
a bill was introduced in Congress on August 5, 1987, that would
impose a two-year moratorium on the issuance of patents for
genetically altered animals.' The introduction of this bill marked
the first time in the history of the patent system that legislation
was introduced to pre-empt a patenting decision by the PTO. 5 6
The bill would amend Chapter 10, title 35, of the United States
Code, 5 7 by adding the following section:
[Section] 105. Patents on animals
During the two-year period beginning on the date of enactment
of this section, vertebrate or invertebrate animals, modified,
altered, or in any way changed through genetic engineering tech-
nology shall not be considered matter within the confines of
patentability and shall not be patentable within the meaning of
section 101 or section 102 or any other provision of this title
and no such patent shall be granted. Any patent previously
granted for any such animal is hereby revoked.'
The author of the bill believes that Congress cannot allow an issue
as important as animal patenting to be decided by the Appeals
Board of the PTO because it is solely within the province of
Congress to establish new patent policy.' 59 The author further main-
tains that "the long term economic, ethical, environmental and
governmental consequences [of patenting genetically altered ani-
mals] . . . are extraordinary, complex and alarming.' ' 60
Biotechnology Center at Ohio University, June 11, 1987) (discussing use of genetically
altered animals as disease models to test drugs).
154. Diamond v. Chakrabarty, 447 U.S. 303, 307 (1980) (quoting Kewanee Oil
Co. v. Bicron Corp., 416 U.S. 470, 480 (1973)).
155. See supra note 32 and accompanying text.
156. See New Bill, supra note 32, at A18, col. 1.
157. H.R. 3119, 100th Cong., 1st Sess. (1987). Congress believes that "such
monumental decisions about the fate of animal life should not be left solely to the
Patent and Trademark Office." Id. at 1(4).
158. Id. at 2.
159. See Hearings: Patents, supra note 2, at 4 (statement of Rep. Rose, July 22,
1987).
160. Id. at 1.
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IV. The Ramifications of Patenting New Forms of Animal Life
A. Should Genetically Altered Animals be Patentable?
The arguments against awarding animal patents stem from fears
concerning the potential consequences of genetic engineering, rather
than the patenting process itself. 161 Yet, if patent protection is
denied, research in genetic engineering will continue:' 62 "A patent
does not confer the right to do something which could otherwise
not be done.' 1 63
Genetically altered animals should not be excluded from patent
protection because of ethical or economic reasons. 164 The patent
system was designed to promote research and invention,' 65 regardless
of ethical or economic considerations.'" Congress intended pat-
entable subject matter to encompass "anything under the sun that
is made by man.' 1 67 The Supreme Court confirmed Congress' intent
in Chakrabarty.168 Since that decision, no legal argument has been
advanced that would justify a change in the broad interpretation
of the Patent Act. 169 Despite the passage of more than eight years,
Congress has refrained from withdrawing patent coverage from
inventions involving living man-made subject matter. 10 Congress'
161. See Hearings: Patents, supra note 2, at 2 (statement of R. Merges, Julius
Silver Fellow in Law, Science and Technology, Columbia Law School, July 22, 1987).
162. See Diamond v. Chakrabarty, 447 U.S. 303, 317 (1980); see also Hearings:
Patents, supra note 2, at 11 (statement of R. Tegtmeyer, Assistant Commissioner of
PTO, June 11, 1987); id. at 8 (statement of N. Seay, Professor of Patent Law at
the University of Wisconsin Law School, Aug. 21, 1987). The denial of patents on
living organisms "will not deter the scientific mind from probing into the unknown
anymore than Canute could command the tides." Chakrabarty, 447 U.S. at 317.
163. See Hearings: Patents, supra note 2, at 8 (statement of W. Duffey on behalf
of Intellectual Property Owners, Inc. and Industrial Biotechnology Association, July
22, 1987).
164. See id.; id. at 7 (statement of N. Seay, Professor of Patent Law at the
University of Wisconsin Law School, Aug. 21, 1987); Man Make Beast, supra note
133, at 72.
165. See supra notes 38-48 and accompanying text.
166. See supra note 164 and accompanying text.
167. Chakrabarty, 447 U.S. at 309 (quoting Committee Reports accompanying
Patent Act of 1952, S. REP. No. 1979, 82d Cong., 2d Sess. 5, reprinted in 1952
U.S. CODE CONG. & ADm. NEws 2394, 2399).
168. See Chakrabarty, 447 U.S. at 308-09 ("Congress plainly contemplated that
the patent laws would be given wide scope").
169. See infra note 171 and accompanying text.
170. See id.
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silence could be interpreted as legislative approval of the Chak-
rabarty decision.' 7'
Congress' sudden interest in the ramifications of Chakrabarty,
i.e., the patenting of multi-celled (animals) as opposed to single-
celled (bacteria) organisms, is unwarranted. 172 The proposed con-
gressional moratorium is also the result of fears regarding the
advancement of genetic engineering. 17 A moratorium on patenting
animals, however, does not directly and sufficiently address these
concerns.7 4 It is true that research is promoted by the granting of
patents. 75 In Chakrabarty, the Court conceded that whether living
organisms "are patentable may determine whether research efforts
are accelerated by the hope of reward or slowed by want of
incentives.' 176 Nevertheless, the inventor will not stop researching
merely because his or her labors will not generate economic re-
ward. 177
If Congress is truly concerned that deleterious effects may result
from genetic research, it should regulate such research.7 8 Through
regulation, Congress could restrict research in areas of genetic
engineering deemed unsafe. 79 Like a patent moratorium, regulation
171. See Hearings: Patents, supra note 2, at 3-4 (statement of M. Ostrach, Senior
Vice-President and General Counsel, Cetus Corp., Aug. 21, 1987). Legislative approval
may not be the only interpretation of Congress' silence, other interpretations may
include-an unwillingness to be politically accountable, a lack of attention concerning
this issue or a failure to recognize the significance of this issue.
172. See id. at 3 ("objections to animal patenting echo the arguments that have
accompanied genetic engineering since its inception and have been refuted by the
experience of the last 15 years"); id. at 21 (statement of G. Karny, intellectual
property attorney, editor of Biotechnology Law Report, Nov. 5, 1987) (to delay
animal patents would be "unprecedented and certainly would be a drastic overre-
action").
173. See Hearings: Patents, supra note 2, at 20-21 (statement of G. Karny, in-
tellectual property attorney, editor of Biotechnology Law Report, Nov. 5, 1987) (risks
from genetic engineering are no greater than risks from traditional breeding techniques);
see also New Bill, supra note 32, at A18, col. 1; New Coalition, supra note 26, at
Cl, cols. 3-4; Strain of Strife, supra note 27, at 56.
174. See Hearings: Patents, supra note 2, at 2-5 (statement of G. Karny, intellectual
property attorney, editor of Biotechnology Law Report, Nov. 5, 1987) (concerns
about technological risks should be addressed by regulation not a patent moratorium).
175. See supra note 13-15 and accompanying text.
176. Diamond v. Chakrabarty, 447 U.S. 303, 317 (1980).
177. See supra note 162 and accompanying text.
178. See Hearings: Patents, supra note 2, at 7 (statement of N. Seay, Professor
of Patent Law at the University of Wisconsin Law School, Aug. 21, 1987); id. at
2, 8 (statement of G. Karny, intellectual property attorney, editor of Biotechnology
Law Report, Nov. 5, 1987).
179. See id. at 1 (statement of A. Sorenson, Assistant Director, Natural & En-
virunmental Resources Division, American Farm Bureau Federation, July 22, 1987).
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would result in limiting economic and scientific gains; 180 however,
regulation would also prevent the harm that the patent moratorium
was drafted to prevent. 8'
B. The Economic, Environmental and Moral Implications of
Genetically Altered Animals
1. Economic Issues
The major economic concern for proponents of a patent mor-
atorium is the loss of the small, family-owned farm. The small
farmer believes he is unable to compete with large corporations in
the food market because he does not have the assets to purchase
products of expensive although efficient genetic engineering tech-
nology.18 2 Although this is a real concern for the small farmer,
opponents of a moratorium believe that changing patent laws may
not be the most realistic way of remedying this situation. 83 Congress
can help small farmers by implementing programs that allow them
to purchase the products of genetic engineering at an affordable
price,' u or by controlling the growth of their competitors (large
corporations) through antitrust laws.185
The risk of losing small farms because of patents on genetically
altered animals must be balanced against the societal benefits that
result from promoting genetic engineering. 18 6 The population of the
world is continuing to grow and expand, 187 causing a decrease in
180. See OTA STUDY, supra note 2, at 355 ("restrictions ... may delay or prevent
important products from reaching the market").
181. The regulatory system is the proper forum to address issues of technological
risks to society. See Hearings.: Patents, supra note 2, at 2-5 (statement of G. Karny,
intellectual property attorney, editor of Biotechnology Law Report, Nov. 5, 1987).
For a discussion of potential harms, see infra notes 182-203 and accompanying text.
182. See supra notes 134-35 and accompanying text.
183. See Hearings: Patents, supra note 2, at 8 (statement of N. Seay, Professor
of Patent Law at the University of Wisconsin Law School, Aug. 21, 1987); id. at
4 (statement of M. Ostrach, Senior Vice-President and General Counsel, Cetus Corp.,
Aug. 21, 1987).
184. See id. at 8 (statement of N. Seay, Professor of Patent Law at the University
of Wisconsin Law School, Aug. 21, 1987).
185. See id. at 2 (statement of A. Sorenson, Assistant Director, Natural & En-
vironmental Resources Division, American Farm Bureau Federation, July 22, 1987).
186. See generally id. at 4-5 (statement of M. Ostrach, Senior Vice-President and
General Counsel, Cetus Corp., Aug. 21, 1987).
187. See id. at 1 (statement of R. Adler, intellectual property attorney, July 22,
1987).
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farmland and an increase in food demand.' The increased pro-
ductivity of food suppliers has paralleled society's increased knowl-
edge in science and technology. 1 9 It is believed that genetically
altered animals will play an important role in the agricultural field. 90
A moratorium on patents will slow down scientific advancement
in this new technology.' 91
2. Environmental Issues
The risks that a genetically altered animal presents to the en-
vironment depend upon the probability of the animal transferring
its altered genes to other organisms in the environment. 92 These
risks are similar in magnitude to the risks of introducing an un-
modified organism into the environment. 193 The assessment of risks
should be based on the nature of the organism that is introduced,
as well as on whether the organism was genetically altered-un-
altered animals can theoretically be as dangerous as genetically
altered animals. 194
The size and complexity of the organism are important factors
used in determining potential risk to the environment.' 95 Livestock
are easily accounted for and physically confined because of their
size and visibility. In nature, genetic material from livestock can
only be transmitted during intraspecies reproduction, which limits
the possible spread of synthetic genes.' 96 As a result, genetically
188. See J. BELDEN, DIRT RICH, DIRT POOR 6, 72-73 (1986) (three million acres
of farmland are lost each year).
189. See G. PETERS & R. LARxN, POPULATION GEOGRAPHY 223, 226 (1983) (patterns
of urbanization); E. HIGBEE, FARmS AND FARMERS IN AN URBAN AGE 8-10 (1963)
(same).
190. See Hearings: Patents, supra note 2, at 4 (statement of W. Duffey on behalf
of Intellectual Property Owners, Inc. and Industrial Biotechnology Association, July
22, 1987) (enormous potential of biotechnology); id. at 15 (statement of R. Adler,
intellectual property attorney, July 22, 1987) (animal patent protection "is imperative
if the world is to feed its malnourished but ever expanding masses"); id. at 2
(statement of W. Brill, Vice-President of Research and Development, Agracetus Co.,
Aug. 21, 1987) ("[g]enetic engineering is going to change agriculture, worldwide").
191. See id. at 8 (statement of N. Seay, Professor of Patent Law at the University
of Wisconsin Law School, Aug. 21, 1987).
192. See Hearings.: Patents, supra note 2, at 9 (statement of T. Wagner, Director
of the Edison Animal Biotechnology Center at Ohio University, June 11, 1987).
193. See id. at 7 (statement of G. Karny, intellectual property attorney, editor of
Biotechnology Law Report, Nov. 5, 1987).
194. See id. The nature of the organism includes the organism's physical size,
ecological niche and complexity.
195. See id. at 9 (statement of T. Wagner, Director of the Edison Animal Bio-
technology Center at Ohio University, June 11, 1987).
196. See id.
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altered large animals should have little impact on the environment. 97
On the other hand, the introduction of fish or oysters into the
environment may have a serious impact on the native wildlife, due
to the difficulty of controlling their reproduction and physical
migration. 19 All told, appropriate government regulation could min-
imize or eliminate any risks caused by the introduction of genetically
altered organisms into the environment. 99
3. Moral or Ethical Issues
A recent government survey, based on a sampling that reflects
the total United States population, reveals that sixty-eight percent
of the American public (eighty-one percent of college graduates)
believe that it is not morally wrong to alter animals genetically. 2°°
Indeed, eighty-two percent of the population support continued
research into genetic engineering. 20 1
Supporters of an animal patent moratorium believe there "must
be ethical constraints to protect the sanctity and dignity of life. ' 20 2
Opponents of a patent moratorium believe ethics and morality
should not dictate the operation of the PTO. 203 Furthermore, they
believe that even if ethics and morality were a consideration in
patent approval, patent laws promoting genetic engineering would
still be supported by a majority of the United States population.20 4
C. The Role of the Patent and Trademark Office
The patent system should not be used as an instrument to regulate
the genetic engineering industry. 205 The goal of the patent system
197. See id.
198. See id. at 4 (statement of M. Mellon, Manager of the Biotechnology Project
of the National Wildlife Federation, Nov. 5, 1987).
199. See id. at 8-9 (statement of G. Karny, intellectual property attorney, editor
of Biotechnology Law Report, Nov. 5, 1987).
200. OFFICE oF TECHNOLOOY ASSESSMENT, U.S. CONO., NEw DEVELOPMENTS IN
BIOTECHNOLOOY: PUBLIC PERCEPTIONS OF BIOTECHNOLOGY 57-58 (1987) (survey was
based on 1,273 telephone interviews) [hereinafter PUBLIC PERCEPTION]; see Public of
2 Minds on Genetic Shifts, N.Y. Times, May 31, 1987, at A21, col. 1 (most people
feel benefits outweigh the risks).
201. See PUBLIC PERCEPTION, supra note 200, at 83. Americans do not hold different
views about the morality of genetic techniques of animal manipulation versus classical
breeding techniques. The moral objection is based on whether animals are manipulated
by any technique. Id. at 59.
202. See Hearings: Patents, supra note 2, at 7 (statement of J. Hoyt, President
of the Humane Society of the United States, June 11, 1987).
203. See supra notes 164-66 and accompanying text.
204. See supra notes 200-01 and accompanying text.
205. See Hearings: Patents, supra note 2, at 2 (statement of G. Karny, intellectual
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is to help promote technological advancement by granting inventors
property rights in their inventions.20 6
The issues raised by patenting genetically altered animals should
be addressed by a regulatory agency. 20 7 The regulation of new
technology has a different goal than patenting. Regulatory agencies
focus on the dangers a new product may pose to the public;
moreover, if the risks are unacceptable or greater than a product's
benefits, a regulatory agency will prohibit or restrict the product's
release.208 The patent office simply has no place in addressing these
safety and ethical issues. 20 9
V. Conclusion
The debate surrounding genetically altered animals will continue
throughout future decades; however, the patent system is not the
proper forum for such a debate. The PTO's proper role is to
determine legal, not ethical issues. The injection of ethics and
morality into the legal process of patent determination will cause
uncertainty in business and scientific communities resulting in ec-
onomic loss.
For the most part, the scientific community has concluded that
the risks posed by genetically altering animals are no greater than
the risks posed by traditional breeding techniques. Nevertheless,
many people have concerns about genetically altered animals and
the technology used to produce them. The current regulatory system
provides the necessary oversight to respond to these concerns. In
fact, administrative agencies can provide adequate regulation over
this field without the need for new legislation.
property attorney, editor of Biotechnology Law Report, Nov. 5, 1987); id. at 7
(statement of N. Seay, Professor of. Patent Law at the University of Wisconsin Law
School, Aug. 21, 1987).
206. See Hearings: Patents, supra note 2, at 2 (statement of G. Karny, intellectual
property attorney, editor of Biotechnology Law Report, Nov. 5, 1987); id. at 1
(statement of R. Adler, intellectual property attorney, July 22, 1987).
207. See id. at 2. For a discussion of the federal regulation of biotechnology, see
Hearings: Patents, supra note 2, at app. (statement of R. Godown, President of the
Industrial Biotechnology Association, Aug. 21, 1987).
208. See Hearings: Patents, supra note 2, at 2-4 (statement of G. Karny, intellectual
property attorney, editor of Biotechnology Law Report, Nov. 5, 1987).
209. See id. at 8 (statement of W. Duffey on behalf -of Intellectual Property
Owners, Inc. and Industrial Biotechnology Association, July 22, 1987); id. at 6
(statement of A. Smith, Vice-President of Integrated Genetics, Nov. 5, 1987); id. at
2-3 (statement of R. Merges, Julius Silver Fellow in Law, Science and Technology,
Columbia Law School, July 22, 1987); Religious Groups Join, supra note 26, at
480.
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The legislation that is currently being proposed, i.e., a moratorium
on animal patents, does not adequately address the problems sought
to be solved by the proponents of the moratorium. Moreover, a
moratorium on patents is unprecedented; Congress has never before
proposed legislation for the purpose of interfering with a PTO
policy decision. Congress should either require greater regulation
in the field of genetic engineering or allow inventors to obtain
animal patents.
The PTO correctly determined that genetically altered animals
are patentable subject matter under section 101; accordingly, there
is no reason to prohibit, delay or revoke patents on genetically
altered animals.
Robert B. Kambic

